top of page
Datový zdroj 2 kopie.png



CB21 Pharma is a pharma company developing and marketing innovative treatments for medical pathologies based on non-psychotropic cannabinoids combined with other active substances.

Develops, innovates, manufactures and markets 21st  century clean label functional cosmetics.

In-house EU-GMP compliant production of:
- Isolated CBD

- Synthetic CBD
- Cannabis sativa extracts

O nás


Our priority is research and development of medical products containing non-psychotropic cannabinoids and other active substances that will benefit patients around the world.

CB21 Pharma aims to be a world leader in the development of pharmaceutical products based on non-psychotropic cannabinoids through evidence-based medicine, development processes and regulatory and manufacturing expertise. A focus on patient benefit is a constant driving force of our research program and achievements to date. By leveraging the most up-to-date science, in-house preclinical and clinical development, and advanced technologies, our R&D department ensures the highest quality new products for the end user.



2018 (November)

Founding of the company


CB21 Pharma obtained a license for manufacturing of APIs and a certificate of good manufacturing practice for API manufacturers.


CB21 Pharma obtained the quality management certification according to EN ISO 13485:2016 for the manufacture of medical devices and the EC CERTIFICATE issued in accordance with Council Directive 93/42/EEC as amended, proving that the medical devices CANNEFF SUP - rectal suppositories and CANNEFF VAG SUP - vaginal suppositories are manufactured under conditions which meet the quality system requirements set out in Annex II, with the exception of point 4, of Council Directive 93/42/EEC as amended. This is the first certificate in the EU issued for Class IIa medical devices containing cannabidiol.


06-portret-Jan_Storch-2019 kopie (1).jpg

Jan Storch
CEO, Co-founder, Pharma R&D

He graduated from the University of Chemistry and Technology in organic chemistry and completed his Ph.D.  at the Czech Academy of Sciences, where he is still the head of the Department of Advanced Materials and Organic Synthesis. His fascination with chemical processes (not only in the human body) has always pushed him one step further. The development of an industrial method for the isolation of one of the most promising and intensively researched substances of recent times – cannabidiol (CBD) – resulted in the founding of the pharmaceutical company CB21 Pharma s.r.o. and the associated brand CANNEFF®, of which he is a co-owner.

Lenka Průšová
COO, Co-founder, Cosmetics R&D & RA

After graduating from the University of Chemistry and Technology, she gradually developed home chemistry products, professional hair products and then fully developed other cosmetic products outside the Czech Republic, including in Toronto. In 2014, after completing a program at Vrije University in Brussels, she became the youngest cosmetics safety assessor in the Czech Republic. Together with her colleague Jan Storch, she launched the CANNEFF® brand, which has revolutionized the cosmetics market (not only) in the Czech Republic. She is the co-owner of CB21 Pharma s.r.o.

CB21Pharma_photos2021-02-web-06 kopie (1).jpg

Antonín Malík
Director QA & QC, Co-founder

He received a master's degree in biochemistry and experience in pharmaceutical analytical methods. He is responsible for the quality management system for APIs and medical devices, implementation of new procedures and process improvement, including supply chains, management of portfolio (medical devices, APIs). Conducting of audits and inspections of manufacturers, incoming materials and final products including internal quality audits. Responsibility for regulatory affairs of APIs and medical devices.


Prof. Ing. Jan Vacek, Ph.D.

President of the Scientific Board

Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University Olomouc

Assoc. Prof. MUDr. Luděk Fiala, Ph.D., MBA.

Member of the Scientific Board

Department of Psychiatry - Charles University in Prague

General University Hospital in Prague

General University Hospital in Pilsen

Prof. PharmDr. Petr Babula, Ph.D.

Member of the Scientific Board

Department head, Department of Physiology, Faculty of Medicine, MU Brno

MUDr. Tomáš Páleníček, Ph.D.

Member of the Scientific Board

Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, NIMH


During the research and development of pharmaceutical products, the products are subjected to pre-clinical and clinical evaluation phases. We test for safety and irritability, verify the effectiveness of the substances used at a given concentration and for a given indication, and determine the correct dosage and potential side effects. We cooperate with our own scientific board and perform clinical testing in faculty hospitals in the Czech Republic. This is what allows us to guarantee the effects of individual products and be the first company with registered medical devices containing CBD. The exceptional effects have been achieved thanks to a unique combination of the latest scientific knowledge and our own preclinical research and the appropriate form of application of the respective preparations.

Výzkum a vývoj


There are many inaccuracies and myths around cannabinoids and public misconceptions that cannabinoids or cannabis can address a wide range of health problems and diseases. However, the truth is that after applying the principles of evidence-based medicine, there is only a narrow group of indications that can be successfully targeted by cannabinoids. Based on the latest evidence from basic research, our preclinical research and clinical trial data, we are focusing our attention on various inflammatory conditions and diseases, psychiatric disorders and pain. These areas cover the following medical disciplines:
















  • Clinical trials for label extension on CANNEFF SUP a CANNEFF VAG SUP are ongoing

  • Pending patent protection

  • Full pipeline of other innovative products in preclinical and clinical development in pilot phase clinical trials and phase 2 clinical trials to evaluate efficacy and safety.



There are many skin types, and for each type an individual approach and the right care is needed. However, the active ingredient cannabidiol works on every skin type. This is simply because in the human body, cannabinoid receptors of the CB1 and CB2 type naturally exist on the surface of every cell. CBD thus activates the cells' natural abilities and stimulates them to regenerative processes, leading to overall skin rejuvenation and improvement.

  • Portfolio of 17 cosmetic product registered in EU

  • Full spectrum of cosmetics applications

  • Scientific combination of ingredients with proven function

  • 1-2 new products developed every 6 months


API - Active substances for pharmaceutical use

Isolated CBD

Synthetic CBD

Cannabis sativa extracts (soon)




Strategic and innovative partnerships allow us to expand our capabilities around the world. We continuously seek for partners in

  • Out-licensing

  • Distribution

  • Product co-development

  • R&D collaborations

  • Strategic alliances


Invoicing details

CB21 Pharma s.r.o.

Studentská 812/6
625 00 Brno 25 - Bohunice

Czech Republic

Company ID: 07563094
VAT No.: CZ07563094
Company registered in the Commercial Register kept by the Regional Court in Brno, file number C108810

Office address

CB21 Pharma s.r.o.

Přívozní 1054/2

170 00 Prague 7

Czech Republic



Write us

Sent. Thank you.

bottom of page